Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Sep;27(8):1612-6.

Using the baseline CT scan to select acute stroke patients for IV-IA therapy

Affiliations
Comparative Study

Using the baseline CT scan to select acute stroke patients for IV-IA therapy

M D Hill et al. AJNR Am J Neuroradiol. 2006 Sep.

Abstract

Background: Intra-arterial therapies for acute ischemic stroke are increasingly available. Intravenous therapy (IV) followed immediately by intra-arterial therapy (IA) has been shown to be safe, but such therapy is resource intensive. Selecting the best patients for this therapy may be accomplished with the use of baseline neuroimaging.

Methods: We used data from the IMS-1 and National Institute for Neurological Disorders and Stroke tissue plasminogen activator (tPA) stroke studies to compare outcomes among IV-IA tPA, IV-tPA, and placebo treatment stratified by the baseline CT scan appearance. The CT scans were scored using the Alberta Stroke Program Early CT (ASPECT) score and dichotomized into ASPECT score > 7 (favorable scan) and ASPECT score < or = 7 (unfavorable scan). Logistic regression was used to assess for an ASPECT score by treatment interaction.

Results: A total of 460 patients was included. Age and sex were similar among the 3 groups. The IV-IA tPA cohort had a higher median National Institutes of Health stroke scale (NIHSS) score (18 versus 17) compared with the IV tPA cohort. The proportion of patients with favorable CT scans (ASPECT score > 7) was lowest in the IV-IA tPA group. A multiplicative interaction effect was shown indicating that patients with an ASPECT score > 7 in the IV-IA cohort were more likely to have a good outcome compared with IV tPA and with placebo. Harm may accrue to patients treated with IV-IA therapy who have an unfavorable baseline CT scan appearance.

Conclusions: Patients with a favorable baseline CT scan appearance are the most likely to benefit from IV-IA therapy. This hypothesis will be tested in the IMS-3 study.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
A, Baseline CT scan at 100 minutes from stroke onset showing a left middle cerebral artery infarct with an ASPECT score of 8. Points are taken off for hypoattenuation of the head of caudate and the lentiform nuclei. Based upon our data, this patient would be an ideal candidate for IV-IA therapy. B, Baseline CT scan at 175 minutes from stroke onset showing a well-evolved right middle cerebral artery infarct with an ASPECT score of 0. Based upon our data, this patient could be harmed by IV-IA therapy.
Fig 2.
Fig 2.
Modified Rankin Scale outcomes at 90 days stratified by the baseline ASPECT score and adjusted using ordered logistic regression for baseline age, NIH Stroke Scale score, onset-to-treatment time, and baseline serum glucose.

Similar articles

Cited by

References

    1. Becker KJ, Brott TG. Approval of the MERCI clot retriever: a critical view. Stroke 2005;36:400–03 - PubMed
    1. Gobin YP, Starkman S, Duckwiler GR, et al. MERCI 1: A phase 1 study of mechanical embolus removal in cerebral ischemia. Stroke 2004;35:2848–54 - PubMed
    1. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003–11 - PubMed
    1. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke 2004;35:904–11 - PubMed
    1. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66–73 - PubMed

Publication types

MeSH terms

Substances